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NOVELTY AND IMPACT 
 
The nationwide study found non-Hodgkin lymphoma and 7 cancers, including squamous cell skin cancer 
and melanoma, were bi-directionally associated with each other. Bi-directional associations may help to 
resolve the role for therapeutic side effects because treatment for two cancers is rarely similar, 
particularly considering primary surgical treatment for skin cancers. The data suggest that an immune 
suppressed state is a key contributing mechanism for second primary cancers and immune therapy in 
patient management will have a clinical impact.     
 
ABSTRACT  
 
Second primary cancers (SPCs) account for an increasing proportion of all cancer diagnoses. It is 
unlikely that prior therapy is solely responsible for SPC risk. To investigate risk of SPC after diagnosis of 
non-Hodgkin lymphoma (NHL) and 10 of its subtypes we conducted a novel bi-directional analysis, 
SPCs after NHL and NHL as SPC. Using the Swedish Family-Cancer Database, we identified 19,833 
individuals with primary NHL diagnosed between 1993 and 2015. We calculated relative risks (RRs) of 
SPCs in NHL survivors and, for bi-directional analysis, risk of NHL as SPC. The overall RRs were 
significantly bi-directionally increased for NHL and 7 cancers. After diagnosis of NHL risks were 
increased for upper aerodigestive tract (RR=1.96), colorectal (1.35), kidney (3.10), bladder (1.54) and 
squamous cell skin cancer (SCC) (4.12), melanoma (1.98) and Hodgkin lymphoma (9.38). The 
concordance between RRs for each bi-directional association between NHL and 31 different cancers was 
highly significant (r= 0.86, P<0.0001).  Melanoma was bi-directionally associated with all 10 subtypes of 
NHL.  The observed bi-directional associations between NHL and cancer suggest that therapy-related 
carcinogenic mechanisms cannot solely explain the findings. Considering that skin SCC and melanoma 
are usually treated by surgery and that these cancers and NHL are most responsive of any cancer to 
immune suppression, the consistent bi-directional results provide population-level evidence that immune 
suppressed state is a key underlying mechanism in the context of SPCs. Furthermore, the quantified risks 
for NHL subtypes have direct clinical application in the management of NHL patients. 
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INTRODUCTION 
 
Non-Hodgkin lymphoma (NHL), the most common hematological malignancy, is a cancer of the lymphatic 
system caused by either B- or T-cell clonal expansion 
1, 2
. Established risk factors for NHL include 
immunosuppression and other types of immunodeficiency or autoimmunity, in addition to chronic 
inflammation induced by viral or other microbial causes 
2
.  
 
There are multiple subtypes of NHL, including, and not restricted, to benign forms of follicular lymphoma, 
small lymphocytic lymphoma and mantle cell lymphoma and aggressive forms of diffuse large B-cell 
lymphoma and Burkitt lymphoma
1
. Perhaps not surprisingly, the epidemiology of NHL has been hampered 
by the changes in NHL classification and studies have been confined to the major subtypes, diffuse large B-
cell lymphoma and follicular lymphoma 
3
. 
 
Until the advent of multidrug chemotherapy to complement radiotherapy in the 1970s, including the CHOP 
regimen (cyclophosphamide, doxorubicin, vincristine, prednisone), and variations thereof, patient outcome 
of NHL was typically poor 
1
. In the late 1990s the monoclonal antibody directed against tumor antigens was 
licensed to be used in combination with chemotherapy and radiotherapy 
1, 2
. Subsequently, other monoclonal 
antibodies, some radioactive labeled, have been developed for treatment of specific NHL subtypes, 
including most recently immune checkpoint inhibitors 
2, 4
.  
 
While the advances in the management of NHL over the past 40 years have undoubtedly led to a markedly 
improved survival, this has come at the cost of an increased number of second primary cancers (SPCs) and 
other treatment-related complications. A number of studies have estimated risks of SPCs after NHL but have 
confined their analyses to the most common NHL subtypes 
5-10
.  
 
Here we report analysis of the Swedish Cancer Registry to assess risks of SPCs following the diagnosis of 
NHL, and also the risk of NHL after the diagnosis of another cancer. The rationale for the bi-directional 
analysis was to understand mechanisms for SPC susceptibility beyond therapeutic side effects and shared 
risk factors 
11, 12
. Indeed, the novel bi-directional analysis of 19,833 NHL patients (including 10 NHL 
subtypes) is a powerful approach in search of evidence for reciprocal relationships between cancer risks 
which may suggest that SPCs may be a model of tumor biology.  
 
PATIENTS AND METHODS 
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The Swedish Family-Cancer Database includes the whole Swedish population organized in families and 
linked to the national Cancer Registry with more than 2 million cancers registered since 1958 
13
. The 
registry is based on compulsory cancer notifications from clinicians and pathologists/cytologists 
14
.  All 
registered NHL cases were histologically verified. While the cancer registry does not publish statistics on 
histological verification of SPCs they are included with primary cancers for which histological verification 
has been around 98% from the 1970s 
15
. An ad hoc study on the diagnostic accuracy of second neoplasms 
found 98% to be correctly classified. 
16
. NHL subtypes were identified through reference to the 10th revision 
of International Classification of Diseases (ICD) in combination with SNOMED (ICD-O2) codes that were 
introduced in 1993. The Swedish Cancer Registry orders tumors by diagnostic date into first, second, third 
etc. primary cancers. This ordering was used either to select NHL as first primary cancer or as SPC after 
another primary cancer. We did not study patients diagnosed with NHL after NHL. NHL patients were 
followed from diagnosis until death, detection of a SPC, emigration or December 31, 2015, whichever came 
first. Person-years and SPCs were categorized according to age (5-year bands), sex, socioeconomic index 
(six groups), region (four groups), calendar year (1993-99, 2000-09, 2010-15), time since NHL diagnosis 
and age at NHL diagnosis. Category-specific incidence rates among NHL patients were multiplied by the 
corresponding person-years at risk to estimate the expected number of malignancies in respective strata. In 
stratified analyses over calendar periods case accrual was stopped at the termination of the period to allow 
uniform follow-up times.  
 
Relative risks (RRs) were assessed by means of incidence rate ratios, regressed over a fixed-effects 
generalized Poisson model. RRs for SPCs were obtained by comparing incidence rates for each SPC in NHL 
patients with respective population background rates for the primary cancer. In the reverse analysis, RRs for 
specific NHLs were considered as SPCs following any primary cancer. Sex, age group, calendar-period, 
socio-economic status and residential area were treated as potential confounders and were adjusted for in the 
regression model. Confidence intervals (CIs) were calculated for 5% level of significance and p-values 
associated with RRs were obtained with two-tailed tests against Chi-square distribution with one degree of 
freedom 
17
.  In referring to differences between RRs we call risks only when they are significant (i.e., 
95%CIs are non-overlapping). The concordance between RRs was assessed by Pearsonian correlation. All 
analyses are performed in SAS (v9.4) or R (v3.3.4).  
 
The study was approved by the Ethical Committee of Lund University. 
 
RESULTS 
 
Of the 19,833 NHL patients, 1,731 developed a SPC with a median follow-up of 4 years. Out of the 940,811 
other cancer patients, 2,571 developed second NHL with a median follow-up of 6 years (Table 1).  
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Risks for SPCs following a diagnosis of NHL and risk of NHL following the diagnosis of 31 non-NHL 
cancers are shown in Table 2. Overall, the risk of SPC was increased 1.53-fold. RRs were significantly 
increased for 12 cancers with the largest RRs being shown for Hodgkin lymphoma (RR: 9.38,), squamous 
cell skin (SCC, 4.12,) and kidney cancers (3.10). Statistically significant RRs of more than 2.00 were also 
documented for leukemia, anal and thyroid tumors. In the reverse analysis, for all non-NHL cancers the risk 
of being diagnosed subsequently with NHL was significantly increased 1.40-fold (Table 2). RRs were 
significantly increased for 14 cancers with the largest RRs being shown for Hodgkin lymphoma (7.29), 
followed by skin SCC (2.44) and testicular cancer (2.29). The concordance between RR for each non-NHL 
cancer following a diagnosis of NHL and RR for NHL following diagnosis of a non-NHL cancer was highly 
statistically significant (r=0.86, P<0.0001).  
 
Sensitivity analysis was performed on data shown in Table 2 by deleting in both of the reciprocal analyses 
the first year of follow-up after first diagnosis of cancer (Supplementary Table 1). No essential differences 
in RRs to Table 2 were noted even though case numbers were reduced. The overall risks for SPC increased 
to 1.62 from 1.53 and the overall risks of NHL as SPC remained at 1.40. 
 
Data in Table 2 were adjusted for sex, age group, calendar-period, socio-economic status and residential 
area. In order to put the data in Table 2 in perspective of some key variables we conducted age- and period-
stratified analyses in Supplementary Tables 2 to 5. Supplementary Table 2 shows RRs separately for SPC 
after NHL when NHL was diagnosed before age 66 or after 65 years. The overall and individual RRs were 
stable in the two age groups and no single RR showed a significant difference, with the exception of 
stomach cancer with a higher risk at the early onset group (95%CIs overlapped). RRs for kidney cancer, 
melanoma and skin SCC were almost equal between the two age groups. We tested a wide range of age cut-
off points and, even though case numbers varied, RRs were stable overall and for kidney cancer, melanoma 
and skin SCC up to age group over 80 years (data not shown). In the reverse analysis (Supplementary Table 
3), NHL as SPC, early onset risks were significantly higher for NHL after kidney cancer and overall; for 
melanoma and skin SCC there were no differences. Stratification by period was done for two almost equally 
long periods (11 and 12 years), the latter covering increasing use of novel therapies (Supplementary Table 
4). Much fewer SPCs were diagnosed in the early period and the overall RR for it was significantly lower 
(1.31) than that for the latter period (1.56). More significant associations for individual SPCs were noted in 
the latter period (e.g., stomach, colorectal and lung cancers) but none were significantly different compared 
to the early period. In the reverse analysis, NHL as SPC, the overall RRs were higher in the latter period but 
the only individual site with a significant difference was colorectal cancer (Supplementary Table 5).           
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Table 3 shows the RRs of all non-NHL cancers following diagnosis of each of the 5 of the major NHL 
subtypes. Statistically significant RRs were shown after mantle cell lymphoma (1.78), marginal zone 
lymphoma (1.70), follicular lymphoma (1.69), lymphoplasmacytic lymphoma (1.64, Waldenstrom 
macroglobulinemia) and diffuse large B-cell lymphoma (1.33). Skin SCC and melanoma risks were 
increased after all 5 NHL subtypes; the RR for skin SCC was 6.20 after mantle cell lymphoma. Lung and 
kidney cancer risks were increased after four NHLs. Risks for upper aerodigestive tract and bladder cancers, 
Hodgkin lymphoma and leukemia were increased after 3 NHLs; the RR for Hodgkin lymphoma was 9.64 
after follicular lymphoma. Rare anal cancer risk was increased to 6.34 after follicular lymphoma. 
 
The results of the reverse analysis, risk of the 5 NHL subtypes as SPC, are shown in Table 4. Melanoma and 
skin SCC were first primaries for five and four subtypes, respectively; RRs were highest for marginal zone 
lymphoma (after melanoma 2.81), for follicular lymphoma (after skin SCC 2.56) and for mantle cell 
lymphoma (after melanoma and skin SCC both 2.46). Testicular cancer was associated with high risks of 
lymphoplasmacytic lymphoma (4.59) and mantle cell lymphoma (5.27). Diffuse large B-cell lymphoma risk 
was increased to 13.76 after Hodgkin lymphoma.  
 
Risks for SPC after 5 rare NHL subtypes are shown in Supplementary Table 6. The overall risks were 
increased and statistically significant for all of them, most for small lymphocytic lymphoma (1.85), followed 
by and anaplastic T-cell lymphoma (1.62). Skin SCC was increased after three of these subtypes, most after 
small lymphocytic lymphoma (7.41). Kidney cancer was increased after two NHL subtypes, cutaneous T-
cell lymphoma and anaplastic T-cell lymphoma both with RRs exceeding 6.00. Melanoma (4.77) and 
leukemia (7.82) were increased after Burkitt lymphoma 
 
Reverse analyses for 5 rare NHL subtypes as SPC are shown in Supplementary Table 7. The overall RRs 
were increased for small lymphocytic lymphoma (2.28) and cutaneous T-cell lymphoma (1.59). Skin SCC 
and cancer of connective tissue were first primaries for three NHL subtypes whereas kidney cancer and 
melanoma were primaries for two subtypes. Small lymphocytic lymphoma was increased to an RR of 13.51 
after testicular cancer. Melanoma, skin SCC and connective tissue cancer each associated with increased 
risks of cutaneous T-cell lymphoma with RRs of 5.93, 4.11 and 9.22, respectively.     
 
Figure 1 shows plots of the RRs over follow-up time since the diagnoses of NHL and non-NHL cancer. 
Following diagnosis of NHL, risks of SPCs were persistent and somewhat increasing for all non-NHL 
cancers, skin SCC and melanoma. For NHL following the diagnosis of a non-NHL cancers, risks were 
moderately decreasing.  
  
DISCUSSION 
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Novel findings of the present study were the demonstration of an increase in overall SPC risk after each of 
the 10 different subtypes of NHL and, conversely, an increase of six of these NHL subtypes as SPC. Skin 
SCC risk was most systematically increased and was found in excess after 8 NHL subtypes, followed by 
melanoma after 7 NHL subtypes and kidney cancer after 6 NHL subtypes. In the reverse analysis on NHL as 
SPC, melanoma and skin SCC were the most common primary cancers, both of which were followed by an 
excess risk of 7 NHL subtypes as SPC. The correlation of the bidirectional associations was highly 
significant P<0.0001. Sensitivity analyses on data for which the first year of follow-up were excluded did 
not change results; this would be expected on cancer cases with practically complete histological 
confirmation. Nor showed age- and period-stratified data unexpected findings on individual cancers, 
including melanoma and skin SCC.   
 
A major strength of this study is that we have avoided ascertainment bias in patient selection because our 
cohort analysis was based on the Swedish population, for which there is near complete case registration with 
long-term follow-up. We do acknowledge, however, that as a limitation of our study we did not have the 
opportunity to incorporate information on treatment.  
 
Therapy-related side effects are generally considered to be the cause of many SPCs. Since chemotherapy 
and radiotherapy regimes are generally used to treat NHL the finding of an increased risk of cancers such as 
those of the lung and colorectum reported herein and documented by others 
5-10
, has a plausible etiology. 
Such a mechanism is not however likely to be solely responsible for any SPC risk as evidenced by the bi-
directional associations we observed. Indeed, given the diversity of cancer treatment across tumor types the 
prominent inter-relationships shown between NHL and kidney, skin, bladder and melanoma invite 
alternative hypotheses. 
 
Aside from some form of shared environmental/lifestyle factors common to cancers, the association of NHL 
with skin SCC and melanoma for which surgery is the primary mode of treatment raises the possibility of 
immune dysfunction playing a role. In keeping with such a postulate is the fact that immunosuppressed 
organ transplantion patients have an increased risk of not only skin SCC and NHL (20-fold) but also kidney 
cancer (15-fold), melanoma, leukemia and anogenital cancers (5-fold) and other cancers 
18
. High risks were 
reported also on lip, oral and pharyngeal cancers, which in the present study were included as minor 
components under ‘upper aerodigestive tract’ cancers 19, 20. The bi-directional spectrum of cancer risk seen 
in the present analysis is reminiscent such observations. Even though observational results may be 
persuasive in suggesting a contribution for immune dysfunction, experimental evidence is required to 
establish it as a mechanistic underpinning. 
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As only a small proportion of NHL patients will have been therapeutically immune suppressed because of 
bone marrow transplantation, for immune dysfuntion to play any role requires an alternative explanation. 
Increasingly it is being recognized that tumors can influence immune function, specifically T-cell function, 
which again mirrors the impact of any iatrogenic immune suppression 
21
. NF-kappaB signaling is a master 
regulator of cancer-associated chronic inflammation which contributes to immunosuppression through 
induction of proinflammatory mediators and activation of immune suppressor cells 
22-24
. Myeloid-derived 
suppressor cells are the main type of tumor-associated macrophages that produce chemokines, cytokines, 
growth factors and proteases which are involved in extracellular matrix remodeling 
25
.  
 
Although there were similarities in the bi-directional risks between NHL subtypes and cancers, there were 
also differences. The highest overall RRs for SPC after NHL were associated with small lymphocytic, 
mantle cell and marginal zone lymphoma with the smallest effect being shown in respect of Burkitt 
lymphoma; these risks were approximately correlated with known survival for these subtypes, and hence 
good survival increases the life-time chance for a SPC. Myeloma risk was high only after 
lymphoplasmacytic lymphoma (Waldenstrom) which could be predicted from the known familial 
association between the two diseases 
26
; consistently, lymphoplasmacytic lymphoma was also increased as 
SPC after myeloma. Other types of unique findings included anal cancer with a high risk after follicular 
lymphoma, high risk of leukemia after mantle cell and Burkitt lymphoma and high risk of kidney cancer 
after cutaneous and anaplastic T-cell lymphoma. In the reverse analysis high risks were noted for diffuse 
large B-cell lymphoma after Hodgkin lymphoma and cervical cancer, the latter even influencing the risk of 
mantle cell lymphoma. Finally, testis cancer was associated with a high risk of small lymphocytic 
lymphoma, mantle cell lymphoma and lymphoplasmacytic lymphoma.    
 
Immune suppression would be a timely explanation to the findings concerning cancers that are known to be 
increased in immunosuppressed patients, in view of the current successes in immune therapy. Immune-
checkpoint inhibitors, which can promote cytotoxic activity of T cells, are effective in some individuals with 
NHL and are gaining wider clinical acceptance 
4, 27, 28
. However, can we exclude other alternative 
explanations, such as shared familial risk, microbial agents or other environmental factors playing a role? 
Given that many cancer susceptibility genes have pleotropic effects it is plausible that a small part of the 
excess risk is enshrined in inherited genetic factors, either through high penetrance alleles or co-inheritance 
of multiple common risk variants. Neither would infection appear as a plausible candidate mechanism 
because of the multiple cancers involved. However, reactivation of endogenous viruses may be important, as 
for example Epstein-Barr virus activation is an essential mechanism in post-transplantation carcinogenesis 
18
. Environmental risk factors, such as smoking, may interact with immunological factors in upper 
aerodigestive tract, kidney and lung cancers. Ultraviolet irradiation, a joint risk factor for skin SCC and 
9 
 
melanoma, has been suggested to be both a risk and protective factors for NHL but large prospective studies 
show no association 
29, 30
.             
 
Generalizability of the results is likely to encompass the cancers with bi-directional significance (NHL, 
upper aerodigestive tract, kidney, bladder, melanoma, skin SCC and Hodgkin) which account for 28% of 
cancers in Sweden 
15
; skin SCC is the most common of these, accounting for 10% of cancers in Sweden. 
Adding also colorectal cancer with modest bi-directional risks would increase the total to 39% of all cancers. 
The main limitation of our study in terms of understanding etiology is our reliance on purely cancer registry 
information. Another point of concern may be that we included all SPCs even though we know that upon 
diagnosis of first cancer a large number of SPCs are synchronously diagnosed. However the level of 
histological verification of all relevant cancers for this study is high and there is no reason to believe that 
diagnostic accuracy would have been compromised. Moreover, the data show that the risk for many SPC 
remains elevated after 15 years. Surveillance for these cancers with elevated risks should be considered for 
integration into ongoing cancer survivorship programs.  
 
In conclusion, we have provided a comprehensive analysis of cancer risks associated with NHL. 
Additionally through analysis of NHL as SPC we propose that immune suppression is a key mechanisms 
responsible for the development of SPCs. Our findings further substantiate the significant cancer risks 
associated with survivorship from NHL and are informative in defining the long-term management of 
patients successfully treated for NHL in terms of surveillance for SPCs. When immune therapy will become 
widely used it will be possible to test the present hypothesis; if correct, the suggested immune-responsive 
SPCs should be suppressed.  
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FIGURE LEGEND  
 
Figure 1 shows trend of RRs and 95%CIs over follow-up time since the diagnoses of NHL (blue) or non-
NHL cancer (golden). For SPC in the kidney (a) the curve is U-shaped but for second NHL after kidney 
cancer the trend was decreasing, reaching 1.00 at 11-15 years. For skin SCC (b) the risk increased markedly 
after the first year and remained stable in further follow-up. RR for second skin SCC was monotonously 
decreasing. Second melanoma (c) risk reached a maximum at 6-10 years of follow-up while that for second 
NHL slowly decreased. The overall trends (d) were steadily increasing for all non-NHL cancer and were 
fairly stable for second NHL.   
13 
 
Table 1. Summary of the cohort  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation: 
SCC, squamous cell carcinoma; SPC, second primary cancer; 
a Percentages in parentheses 
b Inter-quartile distance shown in square brackets 
Total number of individuals followed 12,244,473 
Summary of cases 
I. Number of first primary cancer (except NHL) 940,811 
a. Males 491,412 (52.2) a 
b. Females 449,399 (47.8) 
II. Number of first primary NHL  19,833 
a. Males 11,096 (55.9) 
b. Females 8,737 (44.1) 
III. Number of SPCs in NHL survivors 1,731 
IV. Number of second primary NHLs after other primary cancer 2,571 
Summary of age 
V. Median age at first primary NHL  (years) 69 [58 - 77]b 
VI. Median follow-up time until SPC  (years) 4 [1 - 7] 
VII. Median age at second primary NHL  (years) 76 [69 - 82] 
VIII. Median follow-up time until second primary NHL (years) 6 [2 - 13] 
Summary of NHL subtype  
 No. of SPCs in patients with 
NHL 
No. of second primary NHLs in 
other cancer survivors 
1. Diffuse large B-cell lymphoma 537 1,094 
2. Follicular lymphoma   584 587 
3. Lymphoplasmacytic lymphoma 261 282 
4. Mantle cell lymphoma 123 237 
5. Marginal zone lymphoma 57 62 
6. Small lymphocytic lymphoma 40 112 
7. Burkitt lymphoma 10 22 
8. Mature T-cell lymphoma 49 97 
9. Cutaneous T-cell lymphoma 47 55 
10. Anaplastic T-cell lymphoma 23 23 
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Table 2. Risk of second primary cancer after diagnosis of non-Hodgkin lymphoma (A) and risk of non-Hodgkin lymphoma after 
diagnosis of  non-NHL cancer (B). 
 
Abbreviations: 
N, frequency; RR, relative risk; CI, 95% confidence interval; P, probability; UAT, upper aerodigestive tract; SCC, squamous cell carcinoma;  CUP, cancer of 
unknown primary; 
Bolding indicates statistical significance at 0.05 level
Cancer 
A. Risk of non-NHL cancer after diagnosis of NHL  B. Risk of NHL after diagnosis of non-NHL cancer  
N RR CI lower CI upper P N RR CI lower CI upper P 
UAT 40 1.96 1.44 2.68 <.0001 66 1.71 1.34 2.17 <.0001 
Esophagus 9 0.94 0.51 1.75 0.85 3 0.73 0.28 1.96 0.5363 
Stomach 34 1.52 1.08 2.13 0.015 21 1.01 0.66 1.56 0.947 
Small intestine 3 0.60 0.19 1.87 0.382 6 0.88 0.39 1.95 0.7451 
Colorectum 182 1.35 1.16 1.56 <.0001 269 1.28 1.13 1.44 <.0001 
Anus 7 2.65 1.26 5.58 0.01 3 0.68 0.22 2.12 0.511 
Liver 30 1.29 0.91 1.83 0.159 10 0.89 0.48 1.66 0.7204 
Pancreas 25 0.95 0.64 1.40 0.779 5 0.53 0.22 1.29 0.1617 
Nose 3 2.25 0.72 7.00 0.161 3 1.24 0.40 3.84 0.7099 
Lung 126 1.48 1.25 1.77 <.0001 42 0.88 0.65 1.20 0.4216 
Breast 93 0.88 0.72 1.08 0.221 377 1.28 1.16 1.42 <.0001 
Cervix 1 0.19 0.03 1.36 0.099 53 1.81 1.38 2.37 <.0001 
Endometrium 20 0.74 0.48 1.14 0.175 111 1.36 1.13 1.65 0.0012 
Ovary 9 0.65 0.34 1.25 0.193 37 1.14 0.83 1.58 0.4225 
Other female genitals 4 0.91 0.34 2.42 0.844 9 1.34 0.70 2.57 0.3835 
Prostate 265 0.89 0.79 1.01 0.068 576 1.14 1.05 1.24 0.0027 
Testis  0         28 2.29 1.58 3.32 <.0001 
Other male genitals 4 1.71 0.64 4.56 0.286 2 0.41 0.10 1.65 0.2097 
Kidney 70 3.10 2.45 3.92 <.0001 61 1.57 1.22 2.02 0.0004 
Urinary bladder 83 1.54 1.24 1.91 <.0001 128 1.29 1.09 1.54 0.0037 
Melanoma 83 1.98 1.60 2.44 <.0001 185 1.80 1.56 2.08 <.0001 
Skin (SCC) 314 4.12 3.69 4.60 <.0001 237 2.44 2.14 2.77 <.0001 
Eye 2 0.85 0.21 3.41 0.822 9 1.70 0.92 3.17 0.0918 
Nervous system 24 1.14 0.76 1.70 0.525 46 0.96 0.72 1.29 0.8004 
Thyroid gland 10 2.14 1.15 3.98 0.017 18 0.92 0.58 1.46 0.7152 
Endocrine glands 14 1.16 0.70 1.92 0.576 70 1.37 1.08 1.73 0.009 
Bone 1 1.30 0.18 9.25 0.793 6 2.01 0.90 4.47 0.0881 
Connective tissue 9 1.67 0.87 3.21 0.125 18 1.58 0.99 2.50 0.0535 
Hodgkin lymphoma 15 9.38 5.81 15.15 <.0001 46 7.29 5.46 9.73 <.0001 
Multiple myeloma 14 0.89 0.52 1.50 0.648 24 1.54 1.03 2.30 0.034 
Leukemia 94 2.90 2.36 3.56 <.0001 2 1.75 0.44 7.01 0.4269 
CUP 48 1.31 0.99 1.74 0.061 12 0.67 0.38 1.19 0.1719 
*All 1731 1.53 1.46 1.61 <.0001 2571 1.40 1.34 1.46 <.0001 
15 
 
Table 3. Risk of second primary cancers among survivors of five frequent subtypes of non-Hodgkin lymphoma. 
 
Abbreviations: 
N, frequency; RR, relative risk; CI, confidence interval; P, probability; UAT, upper aerodigestive tract; SCC, squamous cell carcinoma; CUP, cancer of unknown primary;  
Bolding indicates statistical significance at 5% level 
 
 
 
 
 
 
 
 
 
Second cancers 
Diffuse large B-cell lymphoma Follicular lymphoma Lymphoplasmacytic lymphoma Mantle cell lymphoma Marginal zone lymphoma 
N RR 95% CI P N RR 95% CI P N RR 95% CI P N RR 95% CI P N RR 95% CI P 
UAT 14 1.89 1.12 - 3.20 0.017 13 2.06 1.19 - 3.54 0.0094 7 2.53 1.21 - 5.31 0.0141 3 2.33 0.75 - 7.22 0.1435 1 1.66 0.23 - 11.77 0.613 
Stomach 10 0.98 0.52 - 1.81 0.9382 11 1.31 0.72 - 2.36 0.3748 5 1.21 0.50 - 2.91 0.6666 3 1.76 0.57 - 5.45 0.3292 3 3.91 1.26 - 12.14 0.0181 
Colorectum 65 1.31 1.03 - 1.67 0.03 52 1.27 0.97 - 1.67 0.0806 32 1.65 1.16 - 2.33 0.0049 11 1.31 0.72 - 2.36 0.3766 8 1.99 1.00 - 3.99 0.049 
Anus 1 1.09 0.15 - 7.73 0.9326 5 6.34 2.63 - 15.25 <0.0001 1 2.90 0.41 - 20.62 0.2867                 
Liver 15 1.56 0.94 - 2.59 0.085 6 0.75 0.34 - 1.67 0.4833 3 0.77 0.25 - 2.39 0.6511         3 3.91 1.26 - 12.14 0.0181 
Nose 2 3.89 0.97 - 15.59 0.0549                                 
Lung 28 0.94 0.65 - 1.36 0.7511 51 1.93 1.46 - 2.53 <0.0001 19 1.68 1.07 - 2.63 0.0241 10 1.89 1.02 --3.52 0.0436 6 2.41 1.08 - 5.37 0.0311 
Breast 32 0.86 0.61 - 1.22 0.4051 39 1.01 0.74 - 1.38 0.9593 12 0.96 0.55 - 1.70 0.8981 3 0.79 0.25 - 2.44 0.6803 2 0.54 0.14 - 2.18 0.3893 
Cervix         1 0.50 0.07 - 3.53 0.4853                         
Endometrium 11 1.27 0.70 - 2.30 0.4245 6 0.65 0.29 - 1.45 0.2927 2 0.68 0.17 - 2.74 0.5912                 
Ovary 1 0.20 0.03 - 1.43 0.1098 5 0.92 0.38 - 2.21 0.8504 3 1.79 0.58 - 5.54 0.315                 
Prostate 77 0.72 0.58 - 0.90 0.0044 82 1.10 0.89 - 1.37 0.3781 52 1.13 0.86 - 1.48 0.3796 18 0.72 0.45 - 1.14 0.1608 1 0.15 0.02 - 1.05 0.056 
Kidney 20 2.33 1.51 - 3.62 0.0002 25 3.36 2.27 - 4.97 <0.0001 6 1.90 0.85 - 4.23 0.1163 6 3.97 1.79 - 8.85 0.0007 4 5.99 2.25 - 15.96 0.0003 
Urinary bladder 30 1.53 1.07 - 2.19 0.0198 29 1.79 1.24 - 2.58 0.0017 8 1.06 0.53 - 2.12 0.8681 9 2.64 1.38 - 5.08 0.0035 1 0.63 0.09 - 4.49 0.6462 
Melanoma 23 1.58 1.05 - 2.37 0.029 28 2.28 1.57 - 3.30 <0.0001 10 2.04 1.10 - 3.79 0.0245 7 2.84 1.36 - 5.97 0.0057 7 5.85 2.79 - 12.28 <0.0001 
Skin (SCC) 108 3.90 3.23 - 4.72 <0.0001 87 4.30 3.48 - 5.31 <0.0001 51 4.78 3.64 - 6.30 <0.0001 27 6.20 4.25 - 9.04 <0.0001 11 4.75 2.63 - 8.58 <0.0001 
Eye 1 1.20 0.17 - 8.54 0.8542 1 1.38 0.19 - 9.80 0.7479                         
Nervous system 9 1.18 0.62 - 2.28 0.6114 6 0.87 0.39 - 1.94 0.7378 3 1.15 0.37 - 3.55 0.8143 1 0.76 0.11 - 5.41 0.7855 1 1.70 0.24 - 12.08 0.5949 
Thyroid gland 2 1.08 0.27 - 4.31 0.9154 1 0.65 0.09 - 4.61 0.6651 1 1.57 0.22 - 11.14 0.6526 1 3.43 0.48 - 24.37 0.2175         
Endocrine glands 4 0.90 0.34 - 2.40 0.8351 6 1.50 0.67 - 3.33 0.3248 2 1.29 0.32 - 5.16 0.7189         1 2.80 0.39 - 19.90 0.3029 
Bone         1 3.91 0.55 - 27.83 0.1726                         
Connective tissue 2 1.00 0.25 - 3.99 0.9967 3 1.78 0.57 - 5.53 0.3176 2 2.72 0.68 - 10.87 0.1577 1 2.84 0.40 - 20.17 0.2966 1 6.59 0.93 - 46.83 0.0593 
Hodgkin lymphoma 4 4.64 1.74 - 12.37 0.0022 7 9.64 4.59 - 20.25 <0.0001 1 3.33 0.47 - 23.63 0.2294 1 7.21 1.01 - 51.20 0.0483         
Multiple myeloma 2 0.35 0.09 - 1.39 0.1343 4 0.82 0.31 - 2.19 0.6927 6 2.69 1.21 - 5.98 0.0156 2 1.97 0.49 - 7.87 0.3385         
Leukemia 30 2.68 1.87 - 3.83 <0.0001 34 3.66 2.61 - 5.12 <0.0001 8 1.91 0.96 - 3.82 0.0668 12 6.20 3.52 - 10.91 <0.0001 1 1.13 0.16 - 8.00 0.9049 
CUP 13 0.99 0.58 - 1.71 0.9837 20 1.79 1.16 - 2.78 0.0092 7 1.30 0.62 - 2.73 0.4866 4 1.79 0.67 - 4.76 0.2453 1 1.00 0.14 - 7.06 0.996 
All 537 1.33 1.22 - 1.45 <0.0001 584 1.69 1.56 - 1.83 <0.0001 261 1.64 1.45 - 1.85 <0.0001 123 1.78 1.49 - 2.12 <0.0001 57 1.70 1.31 - 2.20 <0.0001 
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Table 4. Risk of five frequent subtypes of non-Hodgkin lymphoma as second primary cancer among survivors of other cancers. 
 
Abbreviations:  
N, frequency; RR, relative risk; CI, confidence interval; P, probability; UAT, upper aerodigestive tract; SCC, squamous cell carcinoma; CUP, cancer of unknown primary; 
Bolding indicates statistical significance at 5% level 
 
First cancer 
Diffuse large B-cell lymphoma Follicular lymphoma Lymphoplasmacytic lymphoma Mantle cell lymphoma Marginal zone lymphoma 
N RR  95% CI P N RR 95% CI P N RR 95% CI P N RR 95% CI P N RR 95% CI P 
UAT 27 1.59 1.09 - 2.32 0.0164 15 1.67 1.01 - 2.78 0.0464 10 2.20 1.18 - 4.10 0.0129 5 1.56 0.65 - 3.77 0.3181 3 3.10 0.99 - 9.66 0.0512 
Stomach 11 1.19 0.66 - 2.15 0.5685 3 0.64 0.21 - 1.98 0.4373 1 0.38 0.05 - 2.69 0.3307 2 1.21 0.30 - 4.85 0.7862 1 2.16 0.30 - 15.36 0.4435 
Colorectum 102 1.06 0.87 - 1.29 0.5534 72 1.58 1.25 - 2.00 0.0001 34 1.36 0.97 - 1.91 0.0767 26 1.55 1.05 - 2.29 0.0275 7 1.35 0.64 - 2.85 0.4385 
Anus 1 0.52 0.07 - 3.66 0.5073 1 0.99 0.14 - 7.04 0.993 1 2.07 0.29 - 14.71 0.467         
Liver 7 1.43 0.68 - 3.00 0.3463 2 0.77 0.19 - 3.08 0.7114     1 1.11 0.16 - 7.89 0.9173     
Nose 1 0.93 0.13 - 6.61 0.9426         2 10.09 2.52 - 40.40 0.0011     
Lung 17 0.82 0.51 - 1.32 0.41 9 0.81 0.42 - 1.56 0.5346 7 1.31 0.62 - 2.74 0.4821 4 1.03 0.39 - 2.75 0.9557 1 0.78 0.11 - 5.53 0.8008 
Breast 144 1.10 0.93 - 1.30 0.2754 113 1.40 1.15 - 1.69 0.0006 35 1.20 0.85 - 1.69 0.2956 25 1.65 1.10 - 2.49 0.0162 12 1.24 0.69 - 2.22 0.4704 
Cervix 25 1.97 1.33 - 2.92 0.0007 14 1.64 0.97 - 2.78 0.0646 4 1.34 0.50 - 3.59 0.5569 4 2.81 1.05 - 7.53 0.0402 1 1.08 0.15 - 7.69 0.9402 
Endometrium 47 1.26 0.94 - 1.68 0.1234 29 1.37 0.95 - 1.98 0.0921 15 1.78 1.06 - 2.97 0.0279 6 1.43 0.64 - 3.22 0.3848 3 1.16 0.37 - 3.62 0.8037 
Ovary 17 1.19 0.74 - 1.92 0.4663 9 0.98 0.51 - 1.88 0.9451 3 0.90 0.29 - 2.80 0.8564 5 3.01 1.25 - 7.30 0.0144 1 0.97 0.14 - 6.91 0.9743 
Prostate 237 1.06 0.92 - 1.21 0.4227 112 1.23 1.01 - 1.49 0.0404 68 1.04 0.81 - 1.34 0.7313 79 1.47 1.16 - 1.86 0.0015 13 1.17 0.66 - 2.08 0.5975 
Testis 6 1.15 0.52 - 2.57 0.7284 5 1.78 0.74 - 4.28 0.1988 5 4.59 1.90 - 11.06 0.0007 6 5.27 2.36 - 11.77 <0.0001     
Kidney 21 1.22 0.79 - 1.87 0.3628 19 2.13 1.36 - 3.35 0.001 7 1.54 0.73 - 3.23 0.2554 4 1.25 0.47 - 3.34 0.6533     
Urinary bladder 57 1.27 0.98 - 1.65 0.0724 26 1.21 0.82 - 1.78 0.3406 17 1.43 0.88 - 2.30 0.1459 10 1.19 0.64 - 2.22 0.585 2 0.84 0.21 - 3.37 0.8027 
Melanoma 68 1.50 1.18 - 1.91 0.0009 41 1.71 1.26 - 2.33 0.0006 18 1.64 1.03 - 2.62 0.0361 20 2.46 1.58 - 3.83 <0.0001 8 2.81 1.39 - 5.67 0.0039 
Skin (SCC) 110 2.39 1.97 - 2.89 <0.0001 50 2.56 1.93 - 3.39 <0.0001 26 2.26 1.53 - 3.33 <0.0001 19 2.46 1.56 - 3.88 0.0001 3 1.26 0.40 - 3.94 0.6913 
Eye 7 2.69 1.28 - 5.65 0.0088     1 1.53 0.22 - 10.89 0.6695         
Nervous system 21 1.01 0.66 - 1.55 0.9557 9 0.77 0.40 - 1.49 0.4417 6 1.21 0.54 - 2.69 0.6439 2 0.55 0.14 - 2.22 0.4042 2 1.56 0.39 - 6.25 0.5317 
Thyroid gland 9 1.06 0.55 - 2.04 0.8591 2 0.42 0.10 - 1.66 0.2148 2 0.97 0.24 - 3.87 0.9614 2 1.43 0.36 - 5.74 0.6115     
Endocrine glands 34 1.51 1.07 - 2.11 0.0174 20 1.68 1.08 - 2.60 0.0213 4 0.70 0.26 - 1.86 0.468 7 1.80 0.86 - 3.79 0.1206 2 1.47 0.37 - 5.89 0.5896 
Bone 4 3.09 1.16 - 8.22 0.0243 1 1.36 0.19 - 9.62 0.7613     1 4.34 0.61 - 30.82 0.1425     
Connective tissue 3 0.60 0.19 - 1.85 0.3688 6 2.24 1.01 - 4.99 0.0482 2 1.57 0.39 - 6.28 0.5246 1 1.11 0.16 - 7.88 0.9178     
Hodgkin lymphoma 37 13.76 9.96 - 19.02 <0.0001 6 3.72 1.67 - 8.30 0.0013         1 6.02 0.84 - 42.82 0.0732 
Multiple myeloma 14 2.05 1.22 - 3.47 0.0072 3 0.84 0.27 - 2.59 0.7559 5 2.69 1.12 - 6.48 0.027         
Leukemia 2 3.91 0.98 - 15.65 0.0538                 
CUP 6 0.77 0.34 - 1.71 0.5136 2 0.48 0.12 - 1.93 0.3033 1 0.47 0.07 - 3.36 0.4545 1 0.72 0.10 - 5.14 0.746     
All 1094 1.27 1.19 - 1.36 <0.0001 587 1.35 1.23 - 1.47 <0.0001 282 1.27 1.12 - 1.44 0.0003 237 1.53 1.32 - 1.76 <0.0001 62 1.22 0.93 - 1.60 0.1597 
